Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Free Cash Flow of -$133.7 million for Q1 2026, up 2.11% year-over-year from -$130.9 million in Q1 2025, and down 22.25% quarter-over-quarter from -$109.3 million in Q4 2025.
Powered by 
Analysis
Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Free Cash Flow for 10 consecutive years, with -$133.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.11% year-over-year to -$133.7 million; the TTM figure through Mar 2026 stood at -$419.2 million (down 13.41% YoY), while the FY2025 annual figure was -$422.1 million, down 20.99% from the prior year.
- Free Cash Flow retreated to -$133.7 million in Q1 2026 per DNLI's latest filing, from -$109.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$49.7 million in Q2 2022 and bottomed at -$136.5 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$89.4 million across 5 years, with a median of -$83.7 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow tumbled 132.77% — and 2024, when it surged 32.19%.
- Denali Therapeutics' Free Cash Flow stood at -$72.4 million in 2022, then tumbled by 54.18% to -$111.6 million in 2023, then increased by 24.97% to -$83.7 million in 2024, then tumbled by 30.59% to -$109.3 million in 2025, then decreased by 22.25% to -$133.7 million in 2026.
- Business Quant data shows DNLI's Free Cash Flow at -$133.7 million in Q1 2026, -$109.3 million in Q4 2025, and -$96.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Denali Therapeutics | 4.18 Bn | 4.18 Bn | 3.51 Mn | -97.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -97.81 Mn |
| Mar 31, 2026 | -133.67 Mn |
| Dec 31, 2025 | -100.06 Mn |
| Sep 30, 2025 | -105.92 Mn |
| Jun 30, 2025 | -79.58 Mn |
| Mar 31, 2025 | -136.55 Mn |
| Dec 31, 2024 | -88.81 Mn |
| Sep 30, 2024 | -63.02 Mn |
| Jun 30, 2024 | -96.01 Mn |
| Mar 31, 2024 | -115.77 Mn |
| Dec 31, 2023 | -100.89 Mn |
| Sep 30, 2023 | -89.43 Mn |
| Jun 30, 2023 | -115.73 Mn |
| Mar 31, 2023 | -64.88 Mn |
| Dec 31, 2022 | -77.51 Mn |
| Sep 30, 2022 | -63.10 Mn |
| Jun 30, 2022 | -45.79 Mn |
| Mar 31, 2022 | -76.15 Mn |
| Dec 31, 2021 | -68.55 Mn |
| Sep 30, 2021 | -43.31 Mn |